Corbus Pharmaceuticals Holdings, Inc. financial data

Symbol
CRBP on Nasdaq
Industry
Pharmaceutical Preparations
Location
500 River Ridge Drive, Norwood, MA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
SAV Acquisition Corp (to 1/10/2014)
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 287 % -17.6%
Debt-to-equity 58.5 % -56.1%
Return On Equity -64.8 % +64.6%
Return On Assets -40.9 % +47.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12M shares +172%
Common Stock, Shares, Outstanding 11.5M shares +160%
Entity Public Float 34.6M USD +9.84%
Common Stock, Value, Issued 1K USD +126%
Weighted Average Number of Shares Outstanding, Basic 11.1M shares +158%
Weighted Average Number of Shares Outstanding, Diluted 11.1M shares +158%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 26.2M USD -6.54%
General and Administrative Expense 14M USD -14.8%
Operating Income (Loss) -40.2M USD +9.59%
Nonoperating Income (Expense) 5.23M USD
Net Income (Loss) Attributable to Parent -35M USD +24.3%
Earnings Per Share, Basic -5.75 USD/shares +47.7%
Earnings Per Share, Diluted -5.75 USD/shares +47.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 23.7M USD +184%
Assets, Current 148M USD +287%
Property, Plant and Equipment, Net 671K USD -47.3%
Operating Lease, Right-of-Use Asset 2.61M USD -25.1%
Other Assets, Noncurrent 0 USD -100%
Assets 152M USD +248%
Accounts Payable, Current 1.15M USD -23.5%
Employee-related Liabilities, Current 2.3M USD +46.3%
Accrued Liabilities, Current 10.5M USD +63.4%
Liabilities, Current 24M USD +46.3%
Operating Lease, Liability, Noncurrent 2.46M USD -38.2%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 26.4M USD -22.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -388K USD -1531%
Retained Earnings (Accumulated Deficit) -454M USD -8.35%
Stockholders' Equity Attributable to Parent 126M USD +1219%
Liabilities and Equity 152M USD +248%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.97M USD +47.3%
Net Cash Provided by (Used in) Financing Activities 107M USD
Net Cash Provided by (Used in) Investing Activities -98.2M USD -1870%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 11.5M shares +160%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 379K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.4M USD +170%
Interest Paid, Excluding Capitalized Interest, Operating Activities 547K USD -14.7%
Deferred Tax Assets, Valuation Allowance 94.9M USD +12.8%
Deferred Tax Assets, Gross 94.9M USD +12.8%
Operating Lease, Liability 3.98M USD -25.5%
Depreciation 611K USD -19.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -35.3M USD +23.3%
Lessee, Operating Lease, Liability, to be Paid 4.36M USD -28.3%
Property, Plant and Equipment, Gross 4.53M USD +0.01%
Operating Lease, Liability, Current 1.52M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.8M USD +2.72%
Lessee, Operating Lease, Liability, to be Paid, Year One 878K USD +2.82%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 386K USD -48.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.69M USD -5.96%
Deferred Tax Assets, Operating Loss Carryforwards 59.1M USD +10.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.69M USD 0%
Additional Paid in Capital 580M USD +35.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.89M USD -12.8%
Interest Expense 652K USD -35.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%